Use of psychostimulants in the management of treatment-resistant major depressive disorder.
作者信息
Pucci Sara L
机构信息
Clinical Pharmacy Practitioner, VA Northeast Ohio Healthcare System, Cleveland, Ohio,
出版信息
Ment Health Clin. 2025 Aug 1;15(4):197-200. doi: 10.9740/mhc.2025.08.197. eCollection 2025 Aug.
Abstract
摘要
相似文献
1
Use of psychostimulants in the management of treatment-resistant major depressive disorder.精神兴奋剂在难治性重度抑郁症治疗中的应用。
Ment Health Clin. 2025 Aug 1;15(4):197-200. doi: 10.9740/mhc.2025.08.197. eCollection 2025 Aug.
2
Psychostimulants in moderate to severe affective disorder: a systematic review of randomized controlled trials.中重度情感障碍中的精神兴奋剂：随机对照试验的系统评价
Nord J Psychiatry. 2013 Dec;67(6):369-82. doi: 10.3109/08039488.2012.752035. Epub 2013 Jan 7.
3
The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis.精神兴奋剂在重度抑郁发作中的疗效：一项系统评价与荟萃分析
J Clin Psychopharmacol. 2017 Aug;37(4):412-418. doi: 10.1097/JCP.0000000000000723.
4
Prescribed psychostimulants and other pro-cognitive medications in bipolar disorder: A systematic review and meta-analysis of recurrence of manic symptoms.双相障碍患者中处方类精神兴奋剂和其他促认知药物：对躁狂症状复发的系统评价和荟萃分析。
Bipolar Disord. 2024 Aug;26(5):418-430. doi: 10.1111/bdi.13440. Epub 2024 Apr 26.
5
The effects of psychostimulant prescription on opioid use disorder among people with co-occurring ADHD.精神兴奋剂处方对同时患有注意力缺陷多动障碍者阿片类物质使用障碍的影响。
J Subst Use Addict Treat. 2025 Aug 26;179:209794. doi: 10.1016/j.josat.2025.209794.
6
Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.治疗苯丙胺类兴奋剂使用障碍的处方精神兴奋剂：随机安慰剂对照试验的系统评价和荟萃分析。
Addiction. 2024 Feb;119(2):211-224. doi: 10.1111/add.16347. Epub 2023 Oct 25.
7
Prevalence and risk factors associated with psychostimulant use among Black individuals: A meta-analysis and systematic review.黑人中与使用精神兴奋剂相关的患病率及风险因素：一项荟萃分析与系统评价
Addict Behav. 2023 Mar;138:107567. doi: 10.1016/j.addbeh.2022.107567. Epub 2022 Dec 2.
8
Efficacy of psychostimulant drugs for cocaine dependence.精神振奋药物治疗可卡因依赖的疗效。
Cochrane Database Syst Rev. 2010 Feb 17(2):CD007380. doi: 10.1002/14651858.CD007380.pub3.
9
Use of nitrous oxide in the treatment of major depressive disorder and treatment-resistant major depressive disorder: A systematic review and meta-analysis nitrous oxide in depressive disorders.一氧化二氮在治疗重度抑郁症和治疗抵抗性重度抑郁症中的应用：系统评价和荟萃分析 一氧化二氮在抑郁症中的应用。
Prog Neuropsychopharmacol Biol Psychiatry. 2024 Feb 8;129:110869. doi: 10.1016/j.pnpbp.2023.110869. Epub 2023 Oct 9.
10
Efficacy of psychostimulant drugs for amphetamine abuse or dependence.精神振奋药物对苯丙胺滥用或依赖的疗效。
Cochrane Database Syst Rev. 2013 Sep 2;2013(9):CD009695. doi: 10.1002/14651858.CD009695.pub2.
本文引用的文献
1
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes.加拿大心境与焦虑治疗网络（CANMAT）2023 年成人重性抑郁障碍管理临床指南更新：加拿大心境与焦虑治疗网络（CANMAT）2023 年成人重性抑郁障碍管理临床指南更新
Can J Psychiatry. 2024 Sep;69(9):641-687. doi: 10.1177/07067437241245384. Epub 2024 May 6.
2
Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis.比较抑郁症治疗药物的疗效和安全性：系统评价和网络荟萃分析。
J Affect Disord. 2021 Sep 1;292:416-423. doi: 10.1016/j.jad.2021.05.119. Epub 2021 Jun 15.
3
The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States.美国治疗抵抗性抑郁症和重度抑郁症的患病率和国家负担。
J Clin Psychiatry. 2021 Mar 16;82(2):20m13699. doi: 10.4088/JCP.20m13699.
4
Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental.治疗抵抗性抑郁症管理的临床指南：法国专家、法国生物精神病学和神经精神药理学协会以及 FondaMental 基金会的法国建议。
BMC Psychiatry. 2019 Aug 28;19(1):262. doi: 10.1186/s12888-019-2237-x.
5
The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis.精神兴奋剂在重度抑郁发作中的疗效：一项系统评价与荟萃分析
J Clin Psychopharmacol. 2017 Aug;37(4):412-418. doi: 10.1097/JCP.0000000000000723.
6
Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.西酞普兰、哌甲酯或二者联合治疗老年抑郁症：一项随机、双盲、安慰剂对照试验
Am J Psychiatry. 2015 Jun;172(6):561-9. doi: 10.1176/appi.ajp.2014.14070889. Epub 2015 Feb 13.
7
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology.英国心理药理学协会关于注意缺陷多动障碍药物治疗推荐的循证指南更新：推荐意见概要。
J Psychopharmacol. 2014 Mar;28(3):179-203. doi: 10.1177/0269881113519509. Epub 2014 Feb 12.
8
Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder.在重度抑郁症部分或完全缓解后仍存在持续性执行功能障碍的成年人中，使用二甲磺酸赖右苯丙胺进行增效治疗。
Neuropsychopharmacology. 2014 May;39(6):1388-98. doi: 10.1038/npp.2013.334. Epub 2013 Dec 6.
9
A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.一项关于左乙拉西坦二甲磺酸盐作为增效治疗在使用依他普仑治疗后仍有残留症状的成人重性抑郁障碍患者中的疗效和安全性的随机对照试验。
J Clin Psychiatry. 2013 Aug;74(8):802-9. doi: 10.4088/JCP.13m08360.
10
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.世界生物精神病学学会联合会（WFSBP）单相抑郁障碍的生物学治疗指南，第 1 部分：单相抑郁障碍的急性和维持治疗更新 2013 年版。
World J Biol Psychiatry. 2013 Jul;14(5):334-85. doi: 10.3109/15622975.2013.804195. Epub 2013 Jul 3.
Zotero 插件